Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome

Ania M Fiksinski, Maude Schneider, Clodagh M Murphy, Marco Armando, Stefano Vicari, Jaume M Canyelles, Doron Gothelf, Stephan Eliez, Elemi J Breetvelt, Celso Arango, Jacob A S Vorstman

Research output: Contribution to journalReview article

Abstract

The purpose of this article is to provide an overview of current insights into the neurodevelopmental and psychiatric manifestations of 22q11.2 deletion syndrome (22q11DS) in children and adolescents. The pediatric neuropsychiatric expression of 22q11DS is characterized by high variability, both interindividual and intraindividual (different expressions over the lifespan). Besides varying levels of intellectual disability, the prevalence of autism spectrum disorders, attention deficit disorders, anxiety disorders, and psychotic disorders in young individuals with 22q11DS is significantly higher than in the general population, or in individuals with idiopathic intellectual disability. Possible explanations for this observed phenotypic variability will be discussed, including genetic pleiotropy, gene-environment interactions, the age-dependency of phenotypes, but also the impact of assessment and ascertainment bias as well as the limitations of our current diagnostic classification system. The implications inferred by these observations aforementioned bear direct relevance to both scientists and clinicians. Observations regarding the neuropsychiatric manifestations in individuals with 22q11DS exemplify the need for a dimensional approach to neuropsychiatric assessment, in addition to our current categorical diagnostic classification system. The potential usefulness of 22q11DS as a genetic model to study the early phases of schizophrenia as well as the phenomenon of neuropsychiatric pleiotropy observed in many CNV's will be delineated. From a clinical perspective, the importance of regular neuropsychiatric evaluations with attention to symptoms not always captured in diagnostic categories and of maintaining equilibrium between individual difficulties and competencies and environmental demands will be discussed.

Original languageEnglish
JournalAmerican Journal of Medical Genetics, Part A
DOIs
Publication statusE-pub ahead of print - Sep 8 2018

Fingerprint

DiGeorge Syndrome
Psychiatry
Pediatrics
Phenotype
Intellectual Disability
Genetic Pleiotropy
Gene-Environment Interaction
Genetic Models
Attention Deficit Disorder with Hyperactivity
Anxiety Disorders
Psychotic Disorders
Schizophrenia
Population

Cite this

Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome. / Fiksinski, Ania M; Schneider, Maude; Murphy, Clodagh M; Armando, Marco; Vicari, Stefano; Canyelles, Jaume M; Gothelf, Doron; Eliez, Stephan; Breetvelt, Elemi J; Arango, Celso; Vorstman, Jacob A S.

In: American Journal of Medical Genetics, Part A, 08.09.2018.

Research output: Contribution to journalReview article

Fiksinski, AM, Schneider, M, Murphy, CM, Armando, M, Vicari, S, Canyelles, JM, Gothelf, D, Eliez, S, Breetvelt, EJ, Arango, C & Vorstman, JAS 2018, 'Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome', American Journal of Medical Genetics, Part A. https://doi.org/10.1002/ajmg.a.40387
Fiksinski, Ania M ; Schneider, Maude ; Murphy, Clodagh M ; Armando, Marco ; Vicari, Stefano ; Canyelles, Jaume M ; Gothelf, Doron ; Eliez, Stephan ; Breetvelt, Elemi J ; Arango, Celso ; Vorstman, Jacob A S. / Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome. In: American Journal of Medical Genetics, Part A. 2018.
@article{db21e8a1a09c406fbda34488c526785f,
title = "Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome",
abstract = "The purpose of this article is to provide an overview of current insights into the neurodevelopmental and psychiatric manifestations of 22q11.2 deletion syndrome (22q11DS) in children and adolescents. The pediatric neuropsychiatric expression of 22q11DS is characterized by high variability, both interindividual and intraindividual (different expressions over the lifespan). Besides varying levels of intellectual disability, the prevalence of autism spectrum disorders, attention deficit disorders, anxiety disorders, and psychotic disorders in young individuals with 22q11DS is significantly higher than in the general population, or in individuals with idiopathic intellectual disability. Possible explanations for this observed phenotypic variability will be discussed, including genetic pleiotropy, gene-environment interactions, the age-dependency of phenotypes, but also the impact of assessment and ascertainment bias as well as the limitations of our current diagnostic classification system. The implications inferred by these observations aforementioned bear direct relevance to both scientists and clinicians. Observations regarding the neuropsychiatric manifestations in individuals with 22q11DS exemplify the need for a dimensional approach to neuropsychiatric assessment, in addition to our current categorical diagnostic classification system. The potential usefulness of 22q11DS as a genetic model to study the early phases of schizophrenia as well as the phenomenon of neuropsychiatric pleiotropy observed in many CNV's will be delineated. From a clinical perspective, the importance of regular neuropsychiatric evaluations with attention to symptoms not always captured in diagnostic categories and of maintaining equilibrium between individual difficulties and competencies and environmental demands will be discussed.",
author = "Fiksinski, {Ania M} and Maude Schneider and Murphy, {Clodagh M} and Marco Armando and Stefano Vicari and Canyelles, {Jaume M} and Doron Gothelf and Stephan Eliez and Breetvelt, {Elemi J} and Celso Arango and Vorstman, {Jacob A S}",
note = "{\circledC} 2018 Wiley Periodicals, Inc.",
year = "2018",
month = "9",
day = "8",
doi = "10.1002/ajmg.a.40387",
language = "English",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Understanding the pediatric psychiatric phenotype of 22q11.2 deletion syndrome

AU - Fiksinski, Ania M

AU - Schneider, Maude

AU - Murphy, Clodagh M

AU - Armando, Marco

AU - Vicari, Stefano

AU - Canyelles, Jaume M

AU - Gothelf, Doron

AU - Eliez, Stephan

AU - Breetvelt, Elemi J

AU - Arango, Celso

AU - Vorstman, Jacob A S

N1 - © 2018 Wiley Periodicals, Inc.

PY - 2018/9/8

Y1 - 2018/9/8

N2 - The purpose of this article is to provide an overview of current insights into the neurodevelopmental and psychiatric manifestations of 22q11.2 deletion syndrome (22q11DS) in children and adolescents. The pediatric neuropsychiatric expression of 22q11DS is characterized by high variability, both interindividual and intraindividual (different expressions over the lifespan). Besides varying levels of intellectual disability, the prevalence of autism spectrum disorders, attention deficit disorders, anxiety disorders, and psychotic disorders in young individuals with 22q11DS is significantly higher than in the general population, or in individuals with idiopathic intellectual disability. Possible explanations for this observed phenotypic variability will be discussed, including genetic pleiotropy, gene-environment interactions, the age-dependency of phenotypes, but also the impact of assessment and ascertainment bias as well as the limitations of our current diagnostic classification system. The implications inferred by these observations aforementioned bear direct relevance to both scientists and clinicians. Observations regarding the neuropsychiatric manifestations in individuals with 22q11DS exemplify the need for a dimensional approach to neuropsychiatric assessment, in addition to our current categorical diagnostic classification system. The potential usefulness of 22q11DS as a genetic model to study the early phases of schizophrenia as well as the phenomenon of neuropsychiatric pleiotropy observed in many CNV's will be delineated. From a clinical perspective, the importance of regular neuropsychiatric evaluations with attention to symptoms not always captured in diagnostic categories and of maintaining equilibrium between individual difficulties and competencies and environmental demands will be discussed.

AB - The purpose of this article is to provide an overview of current insights into the neurodevelopmental and psychiatric manifestations of 22q11.2 deletion syndrome (22q11DS) in children and adolescents. The pediatric neuropsychiatric expression of 22q11DS is characterized by high variability, both interindividual and intraindividual (different expressions over the lifespan). Besides varying levels of intellectual disability, the prevalence of autism spectrum disorders, attention deficit disorders, anxiety disorders, and psychotic disorders in young individuals with 22q11DS is significantly higher than in the general population, or in individuals with idiopathic intellectual disability. Possible explanations for this observed phenotypic variability will be discussed, including genetic pleiotropy, gene-environment interactions, the age-dependency of phenotypes, but also the impact of assessment and ascertainment bias as well as the limitations of our current diagnostic classification system. The implications inferred by these observations aforementioned bear direct relevance to both scientists and clinicians. Observations regarding the neuropsychiatric manifestations in individuals with 22q11DS exemplify the need for a dimensional approach to neuropsychiatric assessment, in addition to our current categorical diagnostic classification system. The potential usefulness of 22q11DS as a genetic model to study the early phases of schizophrenia as well as the phenomenon of neuropsychiatric pleiotropy observed in many CNV's will be delineated. From a clinical perspective, the importance of regular neuropsychiatric evaluations with attention to symptoms not always captured in diagnostic categories and of maintaining equilibrium between individual difficulties and competencies and environmental demands will be discussed.

U2 - 10.1002/ajmg.a.40387

DO - 10.1002/ajmg.a.40387

M3 - Review article

C2 - 30194907

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

ER -